A W Tolcher1. 1. South Texas Accelerated Research Therapeutics (START), San Antonio, USA atolcher@start.stoh.com.
Abstract
Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
Authors: Chia-Wei Li; Seung-Oe Lim; Ezra M Chung; Yong-Soo Kim; Andrew H Park; Jun Yao; Jong-Ho Cha; Weiya Xia; Li-Chuan Chan; Taewan Kim; Shih-Shin Chang; Heng-Huan Lee; Chao-Kai Chou; Yen-Liang Liu; Hsin-Chih Yeh; Evan P Perillo; Andrew K Dunn; Chu-Wei Kuo; Kay-Hooi Khoo; Jennifer L Hsu; Yun Wu; Jung-Mao Hsu; Hirohito Yamaguchi; Tzu-Hsuan Huang; Aysegul A Sahin; Gabriel N Hortobagyi; Stephen S Yoo; Mien-Chie Hung Journal: Cancer Cell Date: 2018-02-12 Impact factor: 31.743
Authors: Francis S Wolenski; Cindy Q Xia; Bingli Ma; Tae H Han; Wen C Shyu; Suresh K Balani Journal: Eur J Drug Metab Pharmacokinet Date: 2018-06 Impact factor: 2.441